ATTENTION : pour chaque essai clinique, les éléments affichés ci-dessous ne sont pas exhaustifs, et le protocole fourni par le promoteur reste l’unique document à consulter pour mener à bien un essai clinique sur centre. Pour plus d'informations, contactez le référent du territoire concerné.

Acronyme / Nom
Situation thérapeutique
Cadre réglementaire
Présentation de l'étude
Acronyme / Nom : SET-HAPLO / SET-HAPLO

Situation thérapeutique : Greffe

Traitement :

Cadre réglementaire : RIPH1

Dernière MÀJ : 15/12/2021
CIM10 - Localisation(s)
Informations principales
Titre : Sequential Chemotherapy Prior to Reduced Intensity Conditioning: Interventional Study in Haploidentical Hematopoietic Stem Cells Transplantation for Patients With Refractory Acute Myeloid Leukemia

Spécialité : Tissus lymphoïde, hématopoïétique et apparentés
Localisation : C92 - Leucémie myéloïde
Informations complémentaires
Schéma : Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with a significant chance of healing in acute myeloid leukemia (AML) or refractory multiple relapses after chemotherapy. However, all patients with an indication of allo-HSC can not benefit because of two limitations: the toxicity of the treatment and graft shortage available.

The goal is to evaluate the efficacy and safety of the combination of an SET followed by haploidentical transplant with post-transplant immune modulation by prophylactic DLI in patients with refractory acute myeloid leukemia or relapsed.

The main objective is to assess overall survival at 2 years in these patients.

Secondary objectives:
- To evaluate the efficacy of this therapeutic strategy in terms of remission of disease, incidence of relapse and relapse-free survival
- To evaluate the non-relapse mortality
- To evaluate the incidence of acute and chronic graft against host disease (GVHD)
- To assess the feasibility of prophylactic injections of donor lymphocytes (pDLI)
- To analyze the post-transplant immune reconstitution

Secondary endpoints:
- partial or complete remission rate by standard criteria at 90 days and then 6, 12 and 24 months after transplantation.
- Relapse incidence and death related to the disease 90 days 6, 12 and 24 months after transplantation Leukemia-free survival at 1 year and 2 years after transplantation
- Cumulative incidence of death not related to relapse at 90 days, 1 year and 2 years after transplantation
- Cumulative incidence of acute and chronic graft against host disease (GVHD)
- Number of patients for whom pDLI was possible and number of pDLI / patient; incidence, severity and treatment of possible secondary GVHD in these patients
- Study of immune reconstitution post-transplant in the peripheral blood 30, 90 and 180 days after transplantation (CD4 lymphocyte levels, CD8, T regulators, Natural Killer cells and B cells)

Methodology, experimental design: Multicenter study in routine care, prospective

All patients will receive, as part of the marketing authorization of the products used, the following regimen:

sequential Packaging (SET):
1. sequential chemotherapy:
> Thiotepa 5 mg / kg / day for 1 day (D-13)
> Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)
> Etoposide 100 mg / m² / day for 4 days (J-12 to J-9)
2. Rest days J-8 and J-6
3. Reduced-intensity conditioning (RIC)
> Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)
> Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)
> Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
4. Graft transfusion: the day D0. A graft of peripheral stem cells is preferred.
Prevention of GVHD:
> Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5
> Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)
> Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)
5. Care supports: according to the protocols of each center
6. lymphocyte injection of prophylactic donor (pDLI): according to the protocols of each center. The following scheme is proposed:
> In the absence of clinical contraindication(GVHD), tapering MMF between days D + 35 and D + 56, then tapering CSA between D + 62 and D + 90
> pDLI: 3 injections from the D + 120 in patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II.
7. Feedback: at baseline and 1, 3, 6, 12 and 24 months after transplant (engraftment, disease response, immune reconstitution, chimerism, GVHD, infection, quality of life).

The treatments evaluated in this strategy are all used in the usual care of patients and follow-up will not be changed.

Phase : NA

Stade : NA

Informations libres de droit
Critères d'inclusion
Critères de non-inclusion
Informations libres de droit
Critères d'inclusion et de non-inclusion
Critères d'inclusion : - Patients with a confirmed diagnosis of acute myeloid leukemia after primary induction treatment failure (persistent leukemia after 2 cycles of induction chemotherapy)
- Patient age ≥ 18 to <60 years
- Cardiac ejection fraction of the left ventricle ≥ 45%
- Lung function - free diffusion capacity for carbon monoxide ≥ 50% of predicted value
- Creatinine clearance ≥ 50 ml / min depending on the CKD-EPI formula
- Availability of an HLA haploidentical donor in the family
- Collection of non-opposition

Critères de non-inclusion : - Uncontrolled invasion of CNS
- Availability of an HLA identical family donor who agreed to donate hematopoietic stem cells OR non-related donor HLA-compatible 10/10 on HLA-A alleles, B, C, and DRB1 DQB1 available and ready to give in 4 weeks to make a decision allograft
- Presence in the patient HLA-specific antibodies directed against an antigen HLA haploidentical donor family
- Karnofsky score <70%
- Patient HIV positive
- Hepatitis B or C or chronic active
- Uncontrolled infection at the time of start packing
- Contraindication to the use of treatments provided by the Protocol
- Previous history of allo-HSC
- No beneficiary of a social security scheme.
Informations relatives au promoteur
Promoteur :
Type de sponsor : Institutionnel
75010 PARIS 10

Coordonnateur :
Centre investigateur
Informations relatives aux investigateurs
Centre investigateur :
Centre Hospitalier Universitaire de Lille - 2 Avenue Oscar Lambret - 59000 LILLE

Investigateur :
Docteur Charles HERBAUX

Secrétariat de recherche

Statut de l'essai : CLOS

MAJ : 13/02/2020